Amenamevir safe and effective treatment option for patients with herpes zoster
Japan: A recent study published in The Journal of Dermatology has shown helicase - primase inhibitor amenamevir (AMNV) to be a safe and effective treatment option in patients with herpes zoster in a real-world clinical setting. Amenamevir showed a favourable safety profile and high cutaneous improvement rates.
In the REWARD study, including 3098 Japanese patients with herpes zoster, the researchers found that amenamevir, a helicase–primase inhibitor, demonstrated high efficacy, with an overall improvement rate of 95.5%. Longer treatment duration, lower pain levels, and less severe cutaneous lesions were associated with higher improvement rates.
Amenamevir was approved for herpes zoster in Japan in 2017. Shinich Imafuku, Department of Dermatology, Fukuoka University, Fukuoka, Japan, and colleagues conducted a 1-month postmarketing observational study to assess the real-world efficacy (pain resolution and cutaneous improvement) and safety of AMNV in patients with herpes zoster.
Of the 3453 patients registered between 2018 and 2020, 3110 were included in the safety analyses. The mean age was 63.7 ± 17.5 years, and 57.9% of patients were aged ≥65 years. Most patients had moderate (41.0%) or mild (53.3%) cutaneous lesions.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.